Volume Alert - MRK 59.72 Merck & Company $MRK Hit a high today of 59.90 Closing the day 10:30 at 59.72 +0.65 +1.10% With a day low of 59.31 and a total volume of 1,935,538.
MRK Recent Posts: http://investorshangout.com/Merck--Company-MRK-51867/
MRK Merck & Company Recent Headline News
Study lifts cloud over heart drugs Zetia, Vytorin
By MARILYNN MARCHIONE - AP - 32 mins ago
CHICAGO (AP) — A major study lifts a cloud around Zetia and Vytorin, blockbuster drugs for lowering cholesterol. The study found that these pills modestly lower the risk of heart attacks and other problems in people at high risk for them — evidence that's been missing for more than a decade as the drugs racked up billions in sales.
MRK: 59.56 (+0.49)
Cramer: Pfizer Deal With Merck Leaves AstraZeneca In the Cold
at The Street - 47 mins ago
TheStreet's Jim Cramer says Pfizer's decision to buy Merck's cancer treatment business likely means an acquisition of AstraZeneca is off the table.
SHPG: 205.78 (+3.16), PFE: 30.14 (-0.20), MRK: 59.56 (+0.49), AZN: 72.15 (-0.70), ABBV: 65.27 (+1.27)
VYTORIN(R) (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study
Business Wire - 49 mins ago
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine VYTORIN(R) (ezetimibe/simvastatin) - which combines simvastatin with the non-statin ZETIA(R) (ezetimibe) -- experienced significantly fewer major cardiovascular events (as measured by a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, re-hospitalization for unstable angina or coronary revascularization occurring at least 30 days after randomization) than patients treated with simvastatin alone. The results from this 18,144-patient study of high-risk patients presenting with acute coronary syndromes were presented today during the late-breaking clinical trials session at the American Heart Association 2014 Scientific Sessions.
MRK: 59.56 (+0.49)
Tracking Seth Klarman's Baupost Group Holdings - Q3 2014 Update
John Vincent - at Seeking Alpha - 2 hrs 20 mins ago
OCN: 21.13 (+0.53), KOS: 9.51 (-0.15), KIN: 8.97 (+0.23), VSAT: 66.35 (-1.26), RFMD: 13.38 (-0.19), EBAY: 54.67 (+0.31), TQNT: 22.24 (-0.36), IDIX: 24.50 (+0.05), SEMI: 17.55 (+0.12), VRTV: 47.13 (+0.98), THRX: 13.16 (-0.07), TBPH: 17.55 (+0.07), IMOS: 21.18 (-0.71), ELOS: 9.99 (-0.30), MU: 31.99 (-0.63), AR: 51.99 (-0.52), NCQ: 0.71 (+0.02), PBF: 27.21 (+0.12), LNG: 70.90 (-0.96), ATRA: 22.93 (-0.24), KERX: 15.19 (-0.02), NG: 2.88 (unch), AOI: 1.85 (unch), FWP: 21.60 (-0.79), BYD: 11.55 (-0.51), ALDW: 17.43 (+0.30), SUNE: 16.49 (-0.44), MRK: 59.56 (+0.49), AVEO: 0.95 (+0.01), AIG: 53.89 (-0.01)
Pfizer Strikes Immuno-oncology Pact with Merck After Abandoning AstraZeneca
at The Street - 2 hrs 30 mins ago
The transaction includes an upfront payment of $850 million to the German company, followed by up to $2 billion in milestone rewards.
PFE: 30.14 (-0.20), MRK: 59.56 (+0.49), AZN: 72.15 (-0.70)
Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today
Business Wire - Mon Nov 17, 7:30AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today said that IMPROVE-IT met its primary endpoint. The results are scheduled to be presented at the American Heart Association Scientific Sessions later today. The data are embargoed by the American Heart Association until the start of the late-breaking clinical trials session at 10:45 a.m. CT today.
MRK: 59.56 (+0.49)
Wall Street Breakfast: Nikkei Dives As Japan Slips Into Recession
Wall Street Breakfast - Seeking Alpha - Mon Nov 17, 5:30AM CST
Outstanding Performance Article Rewards We're excited to announce our latest two Outstanding Performance award winners. Each author receives $2,500. Read more about our Outstanding Performance award winners here . Winner #1: Top long idea...
VRX: 134.50 (+0.29), ACT: 248.06 (+4.29), F: 15.37 (+0.23), FB: 74.21 (-0.67), PFE: 30.14 (-0.20), AGN: 209.75 (+11.10), YHOO: 51.29 (-0.46), PBR: 9.55 (-0.40), DFS: 65.07 (+0.09), DTSI: 32.76 (-0.27), SPY: 204.09 (-0.15), LNKD: 221.69 (-12.20), QQQ: 102.76 (-0.46), AME: 51.16 (-0.54), MRK: 59.56 (+0.49), AOL: 46.58 (+0.54), AZN: 72.15 (-0.70), GM: 32.21 (+0.42), CVEO: 10.60 (-0.04), DD: 70.39 (-0.41)
Pfizer cuts profit outlook after Merck deal
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 3:06AM CST
AZN: 72.15 (-0.70), MRK: 59.56 (+0.49), PFE: 30.14 (-0.20)
MSD Announces Positive Study Investigating the Use of Pembrolizumab Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma
Business Wire - Sun Nov 16, 3:25AM CST
--Findings Presented for First Time at Society of Melanoma Research (SMR) 2014 International Congress
MRK: 59.56 (+0.49)
Merck Announces Positive Study Investigating the Use of KEYTRUDA(R) (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma
Business Wire - Sun Nov 16, 3:25AM CST
--Findings Presented for First Time at Society of Melanoma Research (SMR) 2014 International Congress
MRK: 59.56 (+0.49)
Merck Announces Positive Study Investigating the Use of Pembrolizumab Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma
CNW Group - Sun Nov 16, 3:25AM CST
Pembrolizumab Demonstrated Superiority to Chemotherapy for Primary Endpoint of Progression-Free Survival
MRK: 59.56 (+0.49)
Dow Jones (DJIA) Today: Cisco Systems (CSCO) Leads The Day Higher, Merck (MRK) Lags
at The Street - Fri Nov 14, 10:23AM CST
The Dow component leading the way higher looks to be Cisco Systems (Nasdaq:CSCO), which is sporting a 36-cent gain (+1.4%) bringing the stock to $26.04. Holding back the Dow today is Merck (NYSE:MRK), which is lagging the broader Dow index with a...
MRK: 59.56 (+0.49), CSCO: 26.25 (-0.07)
Merck (MRK) Breaks Through Support at $59.16
Comtex SmarTrend(R) - Fri Nov 14, 10:14AM CST
Merck (NYSE:MRK) has opened bearishly below the pivot of $59.56 today and has reached the first level of support at $59.16. Analysts will be watching for a cross of the next downside pivot targets of $58.79 and $58.02.
MRK: 59.56 (+0.49)
Merck Supports Free Diabetes Screening For More Than 19,000 Community Members in India and Africa on World Diabetes Day, as Part of Merck Diabetes Capacity Advancement Program (CAP)
M2 - Fri Nov 14, 6:21AM CST
African Press Organization (APO)/ - On the occasion of World Diabetes Day (WDD), Merck is conducting Diabetes awareness camps in India, Kenya and Ghana in collaboration with Maharashtra University and Government in India and with Kenya Ministry of health, Diabetes Management and Information center (DMI) and National Diabetes Association of Ghana.
MRK: 59.56 (+0.49)
The Post AASLD Annual Meeting Hepatitis C Landscape
Leonard Yaffe - at Seeking Alpha - Fri Nov 14, 5:15AM CST
JNJ: 108.29 (+0.13), GILD: 100.58 (-1.48), MRK: 59.56 (+0.49), ABBV: 65.27 (+1.27)
Ad Comm meeting approaches to discuss risks of epidural steroid injections
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 10:56AM CST
PFE: 30.14 (-0.20), MRK: 59.56 (+0.49), BMY: 58.23 (+0.28), NVS: 94.50 (+0.55)
Merck Joins Kenya Ministry Of Health Kenya Diabetes Management and Information Center (DMI) to Celebrate The World Diabetes Day
M2 - Thu Nov 13, 9:11AM CST
o Merck supports diabetes medical education and community awareness as part of its Capacity Advancement Program - CAP in Kenya.
MRK: 59.56 (+0.49)
Merck Aims to Support Free Diabetes Screening For More Than 15,000 Community Members in collaboration with Maharashtra University as Part of Its Capacity Advancement Program In India
M2 - Thu Nov 13, 9:11AM CST
o On the occasion of World Diabetes Day, Merck is conducting Diabetes awareness camps at 15 medical colleges in Maharashtra University.
MRK: 59.56 (+0.49)
BIND Therapeutics Offers Great Potential With Upcoming Catalyst
Long Term Bio - at Seeking Alpha - Thu Nov 13, 8:10AM CST
PFE: 30.14 (-0.20), MRK: 59.56 (+0.49), AZN: 72.15 (-0.70), BIND: 10.22 (-0.04)
Gene mutation targeted by Merck's Zetia leads to lower cholesterol levels and reduced heart disease risk
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 8:01AM CST
MRK: 59.56 (+0.49)
MRK Recent Posts: http://investorshangout.com/Merck--Company-MRK-51867/
MRK Merck & Company Recent Headline News
Study lifts cloud over heart drugs Zetia, Vytorin
By MARILYNN MARCHIONE - AP - 32 mins ago
CHICAGO (AP) — A major study lifts a cloud around Zetia and Vytorin, blockbuster drugs for lowering cholesterol. The study found that these pills modestly lower the risk of heart attacks and other problems in people at high risk for them — evidence that's been missing for more than a decade as the drugs racked up billions in sales.
MRK: 59.56 (+0.49)
Cramer: Pfizer Deal With Merck Leaves AstraZeneca In the Cold
at The Street - 47 mins ago
TheStreet's Jim Cramer says Pfizer's decision to buy Merck's cancer treatment business likely means an acquisition of AstraZeneca is off the table.
SHPG: 205.78 (+3.16), PFE: 30.14 (-0.20), MRK: 59.56 (+0.49), AZN: 72.15 (-0.70), ABBV: 65.27 (+1.27)
VYTORIN(R) (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study
Business Wire - 49 mins ago
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine VYTORIN(R) (ezetimibe/simvastatin) - which combines simvastatin with the non-statin ZETIA(R) (ezetimibe) -- experienced significantly fewer major cardiovascular events (as measured by a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, re-hospitalization for unstable angina or coronary revascularization occurring at least 30 days after randomization) than patients treated with simvastatin alone. The results from this 18,144-patient study of high-risk patients presenting with acute coronary syndromes were presented today during the late-breaking clinical trials session at the American Heart Association 2014 Scientific Sessions.
MRK: 59.56 (+0.49)
Tracking Seth Klarman's Baupost Group Holdings - Q3 2014 Update
John Vincent - at Seeking Alpha - 2 hrs 20 mins ago
OCN: 21.13 (+0.53), KOS: 9.51 (-0.15), KIN: 8.97 (+0.23), VSAT: 66.35 (-1.26), RFMD: 13.38 (-0.19), EBAY: 54.67 (+0.31), TQNT: 22.24 (-0.36), IDIX: 24.50 (+0.05), SEMI: 17.55 (+0.12), VRTV: 47.13 (+0.98), THRX: 13.16 (-0.07), TBPH: 17.55 (+0.07), IMOS: 21.18 (-0.71), ELOS: 9.99 (-0.30), MU: 31.99 (-0.63), AR: 51.99 (-0.52), NCQ: 0.71 (+0.02), PBF: 27.21 (+0.12), LNG: 70.90 (-0.96), ATRA: 22.93 (-0.24), KERX: 15.19 (-0.02), NG: 2.88 (unch), AOI: 1.85 (unch), FWP: 21.60 (-0.79), BYD: 11.55 (-0.51), ALDW: 17.43 (+0.30), SUNE: 16.49 (-0.44), MRK: 59.56 (+0.49), AVEO: 0.95 (+0.01), AIG: 53.89 (-0.01)
Pfizer Strikes Immuno-oncology Pact with Merck After Abandoning AstraZeneca
at The Street - 2 hrs 30 mins ago
The transaction includes an upfront payment of $850 million to the German company, followed by up to $2 billion in milestone rewards.
PFE: 30.14 (-0.20), MRK: 59.56 (+0.49), AZN: 72.15 (-0.70)
Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today
Business Wire - Mon Nov 17, 7:30AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today said that IMPROVE-IT met its primary endpoint. The results are scheduled to be presented at the American Heart Association Scientific Sessions later today. The data are embargoed by the American Heart Association until the start of the late-breaking clinical trials session at 10:45 a.m. CT today.
MRK: 59.56 (+0.49)
Wall Street Breakfast: Nikkei Dives As Japan Slips Into Recession
Wall Street Breakfast - Seeking Alpha - Mon Nov 17, 5:30AM CST
Outstanding Performance Article Rewards We're excited to announce our latest two Outstanding Performance award winners. Each author receives $2,500. Read more about our Outstanding Performance award winners here . Winner #1: Top long idea...
VRX: 134.50 (+0.29), ACT: 248.06 (+4.29), F: 15.37 (+0.23), FB: 74.21 (-0.67), PFE: 30.14 (-0.20), AGN: 209.75 (+11.10), YHOO: 51.29 (-0.46), PBR: 9.55 (-0.40), DFS: 65.07 (+0.09), DTSI: 32.76 (-0.27), SPY: 204.09 (-0.15), LNKD: 221.69 (-12.20), QQQ: 102.76 (-0.46), AME: 51.16 (-0.54), MRK: 59.56 (+0.49), AOL: 46.58 (+0.54), AZN: 72.15 (-0.70), GM: 32.21 (+0.42), CVEO: 10.60 (-0.04), DD: 70.39 (-0.41)
Pfizer cuts profit outlook after Merck deal
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 3:06AM CST
AZN: 72.15 (-0.70), MRK: 59.56 (+0.49), PFE: 30.14 (-0.20)
MSD Announces Positive Study Investigating the Use of Pembrolizumab Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma
Business Wire - Sun Nov 16, 3:25AM CST
--Findings Presented for First Time at Society of Melanoma Research (SMR) 2014 International Congress
MRK: 59.56 (+0.49)
Merck Announces Positive Study Investigating the Use of KEYTRUDA(R) (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma
Business Wire - Sun Nov 16, 3:25AM CST
--Findings Presented for First Time at Society of Melanoma Research (SMR) 2014 International Congress
MRK: 59.56 (+0.49)
Merck Announces Positive Study Investigating the Use of Pembrolizumab Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma
CNW Group - Sun Nov 16, 3:25AM CST
Pembrolizumab Demonstrated Superiority to Chemotherapy for Primary Endpoint of Progression-Free Survival
MRK: 59.56 (+0.49)
Dow Jones (DJIA) Today: Cisco Systems (CSCO) Leads The Day Higher, Merck (MRK) Lags
at The Street - Fri Nov 14, 10:23AM CST
The Dow component leading the way higher looks to be Cisco Systems (Nasdaq:CSCO), which is sporting a 36-cent gain (+1.4%) bringing the stock to $26.04. Holding back the Dow today is Merck (NYSE:MRK), which is lagging the broader Dow index with a...
MRK: 59.56 (+0.49), CSCO: 26.25 (-0.07)
Merck (MRK) Breaks Through Support at $59.16
Comtex SmarTrend(R) - Fri Nov 14, 10:14AM CST
Merck (NYSE:MRK) has opened bearishly below the pivot of $59.56 today and has reached the first level of support at $59.16. Analysts will be watching for a cross of the next downside pivot targets of $58.79 and $58.02.
MRK: 59.56 (+0.49)
Merck Supports Free Diabetes Screening For More Than 19,000 Community Members in India and Africa on World Diabetes Day, as Part of Merck Diabetes Capacity Advancement Program (CAP)
M2 - Fri Nov 14, 6:21AM CST
African Press Organization (APO)/ - On the occasion of World Diabetes Day (WDD), Merck is conducting Diabetes awareness camps in India, Kenya and Ghana in collaboration with Maharashtra University and Government in India and with Kenya Ministry of health, Diabetes Management and Information center (DMI) and National Diabetes Association of Ghana.
MRK: 59.56 (+0.49)
The Post AASLD Annual Meeting Hepatitis C Landscape
Leonard Yaffe - at Seeking Alpha - Fri Nov 14, 5:15AM CST
JNJ: 108.29 (+0.13), GILD: 100.58 (-1.48), MRK: 59.56 (+0.49), ABBV: 65.27 (+1.27)
Ad Comm meeting approaches to discuss risks of epidural steroid injections
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 10:56AM CST
PFE: 30.14 (-0.20), MRK: 59.56 (+0.49), BMY: 58.23 (+0.28), NVS: 94.50 (+0.55)
Merck Joins Kenya Ministry Of Health Kenya Diabetes Management and Information Center (DMI) to Celebrate The World Diabetes Day
M2 - Thu Nov 13, 9:11AM CST
o Merck supports diabetes medical education and community awareness as part of its Capacity Advancement Program - CAP in Kenya.
MRK: 59.56 (+0.49)
Merck Aims to Support Free Diabetes Screening For More Than 15,000 Community Members in collaboration with Maharashtra University as Part of Its Capacity Advancement Program In India
M2 - Thu Nov 13, 9:11AM CST
o On the occasion of World Diabetes Day, Merck is conducting Diabetes awareness camps at 15 medical colleges in Maharashtra University.
MRK: 59.56 (+0.49)
BIND Therapeutics Offers Great Potential With Upcoming Catalyst
Long Term Bio - at Seeking Alpha - Thu Nov 13, 8:10AM CST
PFE: 30.14 (-0.20), MRK: 59.56 (+0.49), AZN: 72.15 (-0.70), BIND: 10.22 (-0.04)
Gene mutation targeted by Merck's Zetia leads to lower cholesterol levels and reduced heart disease risk
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 8:01AM CST
MRK: 59.56 (+0.49)
